A Novel Biopsy Device for Ultrasound-Guided Tissue Sampling Evaluated in the Axillary Lymph Nodes: A Prospective, Multi-Center Study (PULSE)

Marc Thill¹, Thorsten Kühn², Uwe Peisker³, Angrit Stachs⁴, Mattea Reinisch⁵, Wolfram Malter⁶, Ines Gruber⁷, Stefan Paepke⁸, Magnus Olsen⁹ and Kai-Uwe Schässburger⁹

¹Agaplesion Markus Hospital, Frankfurt, Germany ²Klinikum Esslingen, Esslingen, Germany ³Hermann-Josef-Krankenhaus, Erkelenz, Germany ⁴Klinikum Südstadt Rostock, Rostock, Germany ⁵Klinken Essen Mitte, Essen, Germany ⁶University Hospital, Köln, Germany ⁷University Hospital Tübingen, Tübingen, Germany ⁸University Hospital r.d. Isar of TU München, München, Germany ⁹Neodynamics AB, Lidingö, Sweden




2023 Disclosures

	Company
(1) Advisory Board	Amgen, AstraZeneca, Biom'Up, Clearcut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Sciences, Grünenthal, GSK, Lilly, MSD, Norgine, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm medical, Pierre-Fabre, Roche, RTI Surgical, Seagen, Sirius Pintuition, Sysmex
(2) Lecture/speaker engagement fees	Amgen, art tempi, AstraZeneca, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Hexal, I-Med-Institute, Lilly, Medtronic, MSD, Novartis, Onkowissen, Organon, Pfizer, pfm medical, Roche, RTI Surgical, Seagen, Sysmex, Viatris, Vifor
(3) Manuscript support	Amgen, Clearcut, Clovis, pfm medical, Organon, Roche, Servier
(4) Trial funding	Endomag, Exact Sciences

Background

- It is the standard of care in Germany for women with suspected or confirmed breast cancer to undergo ultrasound of the ipsilateral axilla prior to surgery in order to detect nodal metastatic disease.
- Women who have abnormal lymph nodes on axillary ultrasound undergo tissue sampling commonly performed with core needle biopsy (14G) under local anaesthetic. Women with proven axillary nodal metastases will then usually undergo axillary node clearance at the same operation as surgical removal of the primary tumour.
- The number of women who need to undergo more than one operation can therefore be minimised by maximising the number of women with axillary metastatic disease in whom this diagnosis is made preoperatively.
- Increasing the volume of tissue removed may increase the diagnostic yield and sensitivity for detection of metastatic deposits [1].
- Due to the vicinity of the lymph nodes to blood vessels and nerves, it poses challenges and limits the practicability of currently used biopsy devices [2].



Axillary Lymph Nodes



Purpose

- A new 14G open-tip vacuum-assisted needle (NeoNavia biopsy system, NeoDynamics, Sweden) intended for increased tissue yield and controlled needle insertion has been developed.
- It has shown higher tissue-yield in bench models compared to core needle [1] and promising first results in the axillary lymph nodes [2][3].
- Purpose is to document the performance characteristics of the NeoNavia biopsy device in the axillary lymph nodes and provide basic insights into the complexity of axillary biopsy procedures.









^[1] Schässburger K-U, Paepke S, Saracco A, Azavedo E, Ekström C, Wiksell H. High velocity pulse biopsy device enables controllable and precise needle insertion and high yield tissue acquisition. Physica Medica. 2018;46:25-31. doi:10.1016/j.ejmp.2017.12.014

^[2] Lee J, Bishop B, Allen S. British Society of Breast Radiology Annual Scientific Meeting 2017. Breast Cancer Research. 2017;19:18-18. doi:10.1186/s13058-017-0903-9

^[3] Ohlinger R, Alwafai Z, Lenz F, Möller S, Zygmunt M, Paepke S. Initial experience with novel micro-pulse biopsy system in axillary lymph node. 39. Jahrestagung der Deutschen Gesellschaft für Senologie. 2019. doi:10.1055/s-0039

The 14G open-tip sampling needle (FlexiPulse) features a front-loaded, open-tip sampling needle and a retractable trocar. This needle design is especially suited for challenging biopsy cases such as small lesions, lesions located near the skin and the axillary lymph nodes.





- Ethically approved German prospective multi-center study (ClinicalTrials.gov ID: NCT03975855).
- 138 patients with clinically/sonographically suspicious axillary lymph nodes at the time of breast cancer diagnosis underwent minimally invasive lymph node tissue sampling following written informed consent.
- A comprehensive set of risk parameters characterizing the anatomic complexity and procedural difficulty of the biopsy was defined and recorded.
- Primary endpoint was success rate (i.e., biopsies from the lymph node).



Inclusion criteria

cT1-4c (multifocality/multicentricity permitted)

Female/male patient age ≥ 18 years

cN+ based on the following criteria (at least one criteria must be met):

lymph node is palpable

cortical asymmetry (focal or diffuse cortical thickening of >3mm) under US

cortex: hilum ratio >2:1 under US

loss of hilum/cortex structure under US

Written informed consent (ICF)


Exclusion criteria

Suspicious lymph nodes after neoadjuvant therapy

No confirmed breast cancer and no abnormality in the breast

Patient uses Marcumar

Pregnant and lactating women



An expert panel established risk parameters to characterize the anatomic complexity of axillary biopsy procedures

Major risk parameter

- LN proximity to vessel <5 mm
- LN proximity to muscle <5 mm
- LN proximity to thoracic wall <5 mm
- LN size <10 mm

Minor risk parameters

- LN proximity to vessel 5-10 mm
- LN proximity to muscle 5-10 mm
- LN proximity to thoracic wall 5-10 mm
- LN size 10-15 mm
- Patient presents with prior axillary surgery, e.g. SLNB, axillary dissection, other / other operations, e.g., benign skin tumors, abscess)
- BMI <18.5
- BMI >30
- LN to skin distance <5 mm
- Patient presents with mobility restriction



Primary Endpoint

Rate of successful biopsies ("success rate")

Secondary Endpoints

- Rate of adverse events
- > Rate of patients presenting with risk parameters for an anatomically complex procedure
- Rate of cases in which pulses facilitated stabilization of the target lesion during needle insertion
- Rate of cases in which pulses facilitated control during needle insertion
- Average number of insertions per case
- Average number of samples per case



Results

- Mean age of the cohort was 56.8 years
- Mean lymph node size of 17.8 mm
- 64 patients presented with <u>at least one major risk factor</u>

# Risk Parameters	# Patients
1	28% (39/138)
2	15%(21/138)
3	3% (4/138)



Major risk parameter*

- LN proximity to vessel <5 mm
- LN proximity to muscle <5 mm
- LN proximity to thoracic wall <5 mm
- LN size <10 mm



Results

Primary Endpoint

Success rate for tissue sampling from the lymph node was 93 % (129/138).

Secondary Endpoints

- Adverse Events
 - Hematoma in the axilla occurred in 1.4% (2/138) of patients (mild). Did not require treatment.
 - Pain in the axilla was reported in 2.9%(4/138) of patients (one mild, one moderate).
- An average of 2.82 samples were obtained per patient with a mean of 1.36 needle insertions.
- Pulses facilitated control during needle insertion in 88% (122/138) of cases.
- Pulses facilitated stabilization of the target lesion during needle insertion in 89% (123/138) of cases.



Conclusions

In challenging cases of axillary biopsies the pulse biopsy device shows a high success rate of tissue sampling (93%). In conclusion;

- Safe and effective: for tissue sampling in axillary lymph nodes.
- Provides controlled needle insertion: pulses were perceived to stabilize the target lesion.
- Multiple samples: obtained with a single insertion.

The pulse biopsy system represents the next generation of tissue sampling, providing high needle control and tissue yield. It is available in the US and Europe (for breast and axillary lymph nodes).









Thank you!

